It is a world-first that pure semaglutide processed with DehydraTECH technology without SNAC will be compared directly to SNAC-enabled Rybelsus® in a multiple week human study.

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar ...

BROCKTON, Mass. — Firefighters are battling a heavy structure fire at a large Brockton home, leading to a large mutual aid response. Fire crews tell Boston 25 that they were dispatched to the ...

RHINELANDER, Wis. (WSAW) - The Rhinelander School District is investigating how a generator failure caused the Hodag Dome to partially collapse, damaging the structure in the process. It happened ...

Reducing glucagon secretion, which lowers glucose production in the liver. Commonly prescribed GLP1-RAs include Ozempic (semaglutide), Victoza (liraglutide), and Trulicity (dulaglutide). Initial ...

CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE ...

Both treatments, as well as the company's weekly weight loss injection Wegovy, contain the active ingredient semaglutide. Wegovy in March 2024 won U.S. approval for slashing the risk of major ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar ...

Semaglutide, the medication better known as Ozempic, reduces the symptoms of a condition that can lead to lower limb amputations in people with diabetes, according to a new study that reinforces ...

The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the ...

AURORA, CO / ACCESS Newswire / March 29, 2025 / A novel study of a semaglutide, a glucagon-like peptide-1 (GLP-1) agonist used to treat type 2 diabetes, obesity and cardiovascular disease, semaglutide ...

Oral semaglutide reduced major cardiovascular events by 14% in patients with type 2 diabetes over nearly 4 years. The trial involved 9650 patients with type 2 diabetes and cardiovascular or kidney ...